Troutman Pepper client Palvella Therapeutics, Inc., a late clinical-stage biopharmaceutical company, recently announced the initial closing of its Series D financing of up to $37.7 million.
This CBM partnership with GTP is focused on moving therapeutics safely and rapidly from concept to clinic by connecting certain of Penn’s established gene therapy platforms with CBM’s manufacturing and analytical capacity.